However, the therapeutic effect of PD-1/PD-L1 inhibitor monotherapy for breast cancer is limited, resulting in more attention on the multiple immune checkpoint blockade therapeutic strategy [62,63]. This evidence concerns the gene PDCD1 and breast carcinoma.